Creative Medical Technology Holdings, Inc. (CELZ) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Creative Medical Technology Holdings, Inc. on February 11, 2022, covering events that occurred on February 9, 2022. The Company is incorporated in Nevada and its common stock trades on The NASDAQ Stock Market LLC under the symbol "CELZ". The filing reports on the execution of new employment agreements with key executive officers.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on executive compensation arrangements.
Material Changes
The primary material change reported is the formalization of employment terms for the Company's Chief Executive Officer and Chief Financial Officer. On February 9, 2022, the Company entered into written Employment Agreements with:
- Timothy Warbington (CEO): Base salary of $330,000 per annum.
- Donald Dickerson (CFO): Base salary of $300,000 per annum.
Both agreements include identical terms regarding duration, bonuses, equity grants, and severance, differing only in the base salary amount.
Guidance, Outlook, and Management Commentary
The filing contains no forward-looking guidance, market outlook, or general management commentary regarding business operations. The specific terms of the new agreements include:
- Term: Three-year initial term with automatic renewal for successive three-year periods unless notice of non-renewal is provided.
- Cash Bonus: Targeted annual cash bonus of 30% of base salary for each executive.
- Equity Grant: Annual stock option grant with a value equal to 30% of base salary, vesting over three years. The initial grant was made on February 9, 2022.
- Severance: In the event of termination without Cause or resignation for Good Reason, the executive is entitled to two years of continued base salary and annual bonuses.
Investor Verification Checklist
- Verify the full text of the Employment Agreements filed as Exhibits 10.1 and 10.2 to review specific definitions of "Cause" and "Good Reason."
- Confirm the impact of the new equity grants on the Company's total share count and potential dilution.
- Review the Company's most recent 10-K or 10-Q filings for actual financial performance data, as this 8-K does not provide revenue or profit figures.
- Assess the Company's cash position to ensure it can support the increased fixed compensation costs and potential severance liabilities.